Adora Animal Health Corporation takes ‘big step forward’ in first US patent | Business | williamsonherald.com

Oct 17, 2024

Mike Vaughn

Franklin-based Adora Animal Health Corporation (Adora) announced that its first US patent, US Patent 12,059,430, has published. The issued patent pertains to processes to prepare a purified form of the active ingredient in Adora’s injectable veterinary generic PSGAG, which is currently marketed by American Regent as Adequan.

Adequan is approved for use in equine and canine applications. There is currently no approved generic for this important veterinary medicine.

Adora’s US-based CMO partner, Kinentia Biosciences (https://kinentia.com), harnessed the power of diafiltration and particle size exclusion technologies to control the purity and manufacturing output of sulfated aminoglycans used in treating arthritic pain and other medical conditions. These technologies represent an improvement in processes to remove low molecular weight reaction impurities and byproducts from existing methods to prepare this high molecular weight and important medicine.

PSGAG is prepared from chondroitin sulfate by sulfating free hydroxyl groups in the molecule followed by chemical digestion into smaller, lower molecular weight fragments and purification to form the active ingredient.

“We are pleased to report the issuance of our first patent related to Adora’s proprietary position with regard to the active ingredient in PSGAG,” said Adora’s CEO and co-inventor, Dr. Thomas D’Ambra. “This is an important first step by improving the quality and purity of our ingredient and sets the stage for continuing activities to gain approval for Adora’s own veterinary injectable version of PSGAG, which we intend to market under the brand name of AMEND.

“As the title of the patent suggests, we are continuing the patent prosecution of additional claims related to topical dosage forms and methods of treatment and look forward to sharing future results as additional products and applications are developed.”

"This patent is a big step forward as the Adora brand continues to grow and expand its product offerings," added Adora’s president Mike Vaughn. "Our innovative products for the human and animal markets are positioned to address a growing category for glycan therapeutics used in treating pain and related medical conditions.”

Visit www.adoralifescience.com for more information.

Log In

Keep it Clean. Please avoid obscene, vulgar, lewd,racist or sexually-oriented language.PLEASE TURN OFF YOUR CAPS LOCK.Don't Threaten. Threats of harming anotherperson will not be tolerated.Be Truthful. Don't knowingly lie about anyoneor anything.Be Nice. No racism, sexism or any sort of -ismthat is degrading to another person.Be Proactive. Use the 'Report' link oneach comment to let us know of abusive posts.Share with Us. We'd love to hear eyewitnessaccounts, the history behind an article.